Boehringer Ingelheim India Profile
Key Indicators
- Authorised Capital ₹ 6.47 Cr
as on 24-10-2024
- Paid Up Capital ₹ 6.47 Cr
as on 24-10-2024
- Company Age 21 Year, 8 Days
- Last Filing with ROC 31 Mar 2024
- Revenue -4.83%
(FY 2023)
- Profit -34.88%
(FY 2023)
- Ebitda -28.10%
(FY 2023)
- Net Worth -8.09%
(FY 2023)
- Total Assets 11.75%
(FY 2023)
About Boehringer Ingelheim India
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.47 Cr and a paid-up capital of Rs 6.47 Cr, as per Ministry of Corporate Affairs (MCA) records.
Gagandeep Bedi, Sandipkumar Agrawal, Sanjay Srivastava, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2003PTC143499
- Company No.
143499
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Dec 2003
- Date of AGM
20 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Boehringer Ingelheim India?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Gagandeep Bedi  | Managing Director | 24-Aug-2023 | Current |
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sandipkumar Agrawal | Director | 11-Oct-2017 | Current |
| Sanjay Srivastava | Director | 21-Nov-2022 | Current |
| Shriya Oak | Director | 12-Jun-2024 | Current |
Financial Performance and Corporate Structure Insights of Boehringer Ingelheim India.
Boehringer Ingelheim India Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.83% decrease. The company also saw a substantial fall in profitability, with a 34.88% decrease in profit. The company's net worth dipped by a decrease of 8.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Boehringer Ingelheim India?
In 2023, Boehringer Ingelheim India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Boehringer Ingelheim India?
Boehringer Ingelheim India has a workforce of 744 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Boehringer Ingelheim India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Boehringer Ingelheim India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
